Investigational drug · Phase 3
SYH2053
Not approved by FDA. In 4 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Non-familial Hypercholesterolemia and Mixed Hyperlipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), Hypercholesterolemia and Mixed Hyperlipidemia.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 8, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
4
3 still active
All registered trials
7
Any phase or sponsor naming "SYH2053"
First trial start
2024
Dec 3, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SYH2053", any sponsor or status.
Conditions studied
As listed on its trial records.
- Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
- Heterozygous Familial Hypercholesterolemia (HeFH)
- Hypercholesterolemia and Mixed Hyperlipidemia
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "SYH2053" as an intervention, largest first.
- A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed Hyperlipidemia on a Background of Lipid-lowering TherapyPivotal-lookingNot yet recruiting
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT07421284 · 900 participants (planned) · Start Mar 31, 2026 · Primary completion Dec 31, 2027
Drug: SYH2053/placebo injection · For: Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Sites: Beijing, China
- A Study to Evaluate the Safety, Efficacy of SYH2053 as Monotherapy in Chinese Participants With Non-familial Hypercholesterolemia or Mixed HyperlipidemiaPivotal-lookingRecruiting
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT07421297 · 760 participants (planned) · Start Feb 28, 2026 · Primary completion Dec 31, 2027
Drug: SYH2053 injection · For: Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
Sites: Beijing, China · 2 sites in all
- A Study to Evaluate the Safety, Efficacy of SYH2053 in Chinese Participants With Non-familial Hypercholesterolemia and Mixed HyperlipidemiaPivotal-lookingCompleted
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT07421232 · 156 participants · Start Dec 3, 2024 · Primary completion Aug 30, 2025
Drug: SYH2053/placebo injection; Inclisiran (Leqvio®) 300mg · For: Hypercholesterolemia and Mixed Hyperlipidemia
Sites: Beijing, China
- A Study to Evaluate the SYH2053 Injection in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)Pivotal-lookingRecruiting
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT07465263 · 135 participants (planned) · Start Mar 31, 2026 · Primary completion Feb 28, 2028
Drug: SYH2053 Injection; Placebo Injection · For: Heterozygous Familial Hypercholesterolemia (HeFH)
Sites: Beijing, China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT06229548 · 39 participants · Start Jan 8, 2024 · Primary completion Dec 23, 2024
Drug: SYH2053; Placebo · For: Hyperlipemia
Sites: Beijing, China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT07938034 · 24 participants (planned) · Start Jul 15, 2026 · Primary completion Jul 15, 2027
Drug: SYH2053 · For: Renal Impairment
Sites: Beijing, China
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.Industry
NCT07943520 · 24 participants (planned) · Start Aug 15, 2026 · Primary completion Aug 15, 2027
Drug: SYH2053 · For: Hepatic Impairment
Sites: Jinan, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Non-familial Hypercholesterolemia and Mixed Hyperlipidemia
- IBI306Phase 31 trial
Innovent Biologics (Suzhou) Co. Ltd. · Non-Familial Hypercholesterolemia and Mixed Hyperlipidemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.